A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia

Trial Profile

A Phase I/II Open Label, Dose-Escalation Study to Assess the Safety and Tolerability of VM202 in Subjects With Chronic Refractory Myocardial Ischemia

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2015

At a glance

  • Drugs Hepatocyte growth factor gene therapy (Primary)
  • Indications Myocardial ischaemia
  • Focus Adverse reactions
  • Sponsors ViroMed
  • Most Recent Events

    • 08 Feb 2015 Status changed from not yet recruiting to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
    • 18 Jan 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
    • 18 Jan 2015 Planned primary completion date changed from 1 Jul 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top